BioLife Solutions, Inc.(BLFS)Earnings, Financials & Key Ratios

BLFS•NASDAQ

$21.75

$1.05B mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryDiagnostics and life science tools

AboutBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Show more

Revenue$96M+17.0%
EBITDA-$12M-891.8%
Net Income-$12M+39.9%
EPS (Diluted)-0.25+43.2%
Gross Margin64.56%-1.1%
EBITDA Margin-12.61%-776.9%
Operating Margin-12.61%-45.5%
Net Margin-12.61%+48.6%
ROE-3.37%+42.8%
ROIC-2.73%-60.1%
Debt/Equity0.03-65.7%
Interest Coverage-4.48+54.8%

Technical→

BLFS Key Insights

BioLife Solutions, Inc. (BLFS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 20.9% free cash flow margin
✓Strong 5Y sales CAGR of 14.9%

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

BLFS Price & Volume

BioLife Solutions, Inc. (BLFS) stock price & volume — 10-year historical chart

Loading chart...

BLFS Growth Metrics

BioLife Solutions, Inc. (BLFS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years31.03%

5 Years14.88%

3 Years8.07%

TTM47.35%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM39.9%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM44.06%

Return on Capital

10 Years-7.98%

5 Years-4.43%

3 Years-3.74%

Last Year-3.24%

BLFS Recent Earnings

BioLife Solutions, Inc. (BLFS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.04

Est $0.02

+300.0%

Revenue

$25M

Est $24M

+2.9%

Q4 2025

Nov 6, 2025

EPS

$0.04

Est $0.00

+1900.0%

Revenue

$28M

Est $26M

+9.3%

Q3 2025

Aug 7, 2025

EPS

$0.33

Est $0.03

-888.5%

Revenue

$25M

Est $26M

-1.0%

Q2 2025

May 8, 2025

EPS

$0.04

Est $0.05

+182.4%

Revenue

$24M

Est $22M

+7.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.04vs $0.02+300.0%	$25Mvs $24M+2.9%
Q4 2025	Nov 6, 2025	$0.04vs $0.00+1900.0%	$28Mvs $26M+9.3%
Q3 2025	Aug 7, 2025	$0.33vs $0.03-888.5%	$25Mvs $26M-1.0%
Q2 2025	May 8, 2025	$0.04vs $0.05+182.4%	$24Mvs $22M+7.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
BFLYButterfly Network, Inc.Direct Competitor	1.19B	4.55	-14.68	18.96%	-73.63%	-36.79%	0.10
AZTAAzenta, Inc.Direct Competitor	846.61M	18.38	-15.07	3.55%	-29.86%	-10.69%	0.06
CYRXCryoport, Inc.Direct Competitor	637.01M	12.69	9.06	-24.47%	42.17%	16.16%	0.46
RGENRepligen CorporationProduct Competitor	7.09B	125.76	146.23	16.36%	6.73%	2.46%	0.33
NVCRNovoCure LimitedProduct Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
NVSTEnvista Holdings CorpProduct Competitor	4.5B	27.06	96.64	8.32%	2.41%	2.18%	0.55
FELEFranklin Electric Co., Inc.Product Competitor	4.46B	100.98	31.07	5.44%	6.91%	11.44%	0.21
BNGOBionano Genomics, Inc.Product Competitor	13.64M	1.27	-0.26	-7.37%	-92.59%	-56.22%	0.16

Compare BLFS vs Peers

BioLife Solutions, Inc. (BLFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BFLY

Most directly comparable listed peer for BLFS.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BLFS against a more recognizable public peer.

Peer Set

Compare Top 5

vs BFLY, AZTA, CYRX, RGEN

BLFS Income Statement

BioLife Solutions, Inc. (BLFS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	11.02M	19.74M	27.37M	48.09M	119.16M	76.24M	75.86M	82.25M	96.21M
Revenue Growth %	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	-0.5%	8.44%	16.97%
Cost of Goods Sold	4.28M	6.22M	8.86M	20.65M	90.31M	29.33M	96.52M	28.58M	34.1M
COGS % of Revenue	38.8%	31.49%	32.36%	42.93%	75.79%	38.47%	127.24%	34.75%	35.44%
Gross Profit	6.75M▲ 0%	13.53M▲ 100.5%	18.51M▲ 36.9%	27.44M▲ 48.2%	28.85M▲ 5.1%	46.91M▲ 62.6%	46.75M▼ 0.3%	53.67M▲ 14.8%	62.12M▲ 15.7%
Gross Margin %	61.2%	68.51%	67.64%	57.07%	24.21%	61.53%	61.63%	65.25%	64.56%
Gross Profit Growth %	41.16%	100.49%	36.88%	48.23%	5.12%	62.63%	-0.34%	14.8%	15.74%
Operating Expenses	7.8M	9.86M	18.17M	30.77M	73.34M	52.83M	117.58M	60.8M	62.94M
OpEx % of Revenue	70.79%	49.96%	66.4%	63.99%	61.55%	69.3%	155%	73.92%	65.41%
Selling, General & Admin	6.61M	8.56M	14.05M	21.02M	48.09M	44.93M	55.97M	50.15M	55.37M
SG&A % of Revenue	59.96%	43.38%	51.34%	43.71%	40.36%	58.93%	73.79%	60.97%	57.55%
Research & Development	1.19M	1.3M	4.12M	6.72M	11.82M	14.8M	18.8M	7.91M	7.57M
R&D % of Revenue	10.82%	6.57%	15.05%	13.97%	9.92%	19.41%	24.78%	9.62%	7.86%
Other Operating Expenses	0	0	0	3.03M	13.43M	-6.89M	42.81M	2.74M	0
Operating Income	-1.06M▲ 0%	3.66M▲ 446.8%	-781K▼ 121.3%	-3.33M▼ 326.6%	-35.16M▼ 955.2%	-5.92M▲ 83.2%	-23.44M▼ 295.7%	-7.13M▲ 69.6%	-12.13M▼ 70.2%
Operating Margin %	-9.58%	18.55%	-2.85%	-6.93%	-29.51%	-7.77%	-30.9%	-8.67%	-12.61%
Operating Income Growth %	78.23%	446.78%	-121.33%	-326.63%	-955.22%	83.15%	-295.75%	69.59%	-70.15%
EBITDA	-717K	4M	1.53M	1.74M	-22.3M	14.04M	-11.14M	1.53M	-12.13M
EBITDA Margin %	-6.51%	20.26%	5.58%	3.61%	-18.71%	18.41%	-14.69%	1.86%	-12.61%
EBITDA Growth %	84.01%	657.88%	-61.8%	13.61%	-1384.27%	162.95%	-179.41%	113.75%	-891.78%
D&A (Non-Cash Add-back)	339K	338K	2.31M	5.07M	12.87M	19.96M	12.29M	8.66M	0
EBIT	-2.13M	-25M	770K	-3.59M	-30.65M	-10.68M	-25.63M	-7.13M	0
Net Interest Income	-454K	276K	501K	40K	-485K	-687K	-1.81M	-719K	0
Interest Income	1K	281K	506K	58K	0	0	0	0	0
Interest Expense	455K	5K	5K	18K	485K	687K	1.81M	719K	2.71M
Other Income/Expense	-1.46M	-28.67M	-2.98M	0	6.13M	1.07M	4.97M	-4.3M	49K
Pretax Income	-2.52M▲ 0%	3.27M▲ 229.9%	9.52M▲ 191.5%	-1.28M▼ 113.5%	-29.03M▼ 2165.9%	-4.85M▲ 83.3%	-18.47M▼ 281.0%	-11.43M▲ 38.1%	-12.08M▼ 5.7%
Pretax Margin %	-22.82%	16.54%	34.78%	-2.66%	-24.36%	-6.36%	-24.35%	-13.89%	-12.56%
Income Tax	0	396K	-1.54M	-3.26M	-20.12M	-5.24M	24K	-38K	49K
Effective Tax Rate %	0%	12.12%	-16.19%	254.8%	69.31%	108%	-0.13%	0.33%	-0.41%
Net Income	-2.52M▲ 0%	3.27M▲ 229.9%	-1.66M▼ 150.7%	2.67M▲ 261.0%	-8.91M▼ 434.0%	-139.81M▼ 1469.4%	-66.43M▲ 52.5%	-20.18M▲ 69.6%	-12.13M▲ 39.9%
Net Margin %	-22.82%	16.54%	-6.05%	5.55%	-7.48%	-183.38%	-87.57%	-24.54%	-12.61%
Net Income Growth %	63.42%	229.86%	-150.73%	260.95%	-434.01%	-1469.43%	52.49%	69.61%	39.9%
Net Income (Continuing)	-2.52M	-25M	0	1.98M	-8.91M	388K	-18.45M	-11.39M	-12.13M
Discontinued Operations	0	0	0	0	0	-140.19M	0	-8.8M	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.21▲ 0%	-1.56▼ 642.9%	-0.09▲ 94.5%	-0.06▲ 29.8%	-0.23▼ 284.6%	-3.29▼ 1330.4%	-1.52▲ 53.8%	-0.44▲ 71.1%	-0.25▲ 43.2%
EPS Growth %	61.11%	-642.86%	94.54%	29.81%	-284.62%	-1330.43%	53.8%	71.05%	43.18%
EPS (Basic)	-0.21	-1.56	-0.09	0.07	-0.23	-3.29	-1.52	-0.44	-0.25
Diluted Shares Outstanding	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M	48.65M
Basic Shares Outstanding	13.26M	16.26M	19.46M	27.31M	38.5M	42.48M	43.72M	46.07M	47.75M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

BLFS Balance Sheet

BioLife Solutions, Inc. (BLFS) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	9.93M	37.56M	24.18M	114.71M	125.86M	138.45M	120.6M	148.76M	120.18M
Cash & Short-Term Investments	6.66M	30.66M	6.45M	90.46M	69.87M	62.7M	44.18M	104.58M	120.18M
Cash Only	6.66M	30.66M	6.45M	90.46M	69.87M	19.44M	27.9M	95.39M	0
Short-Term Investments	0	0	0	0	0	43.26M	16.29M	9.2M	120.18M
Accounts Receivable	1.02M	3.04M	5.34M	8.01M	23.22M	33.94M	18.66M	9.17M	0
Days Sales Outstanding	33.81	56.3	71.28	60.77	71.12	162.47	89.77	40.68	-
Inventory	1.85M	3.51M	11.12M	11.6M	28.34M	34.9M	43.46M	29.01M	0
Days Inventory Outstanding	157.66	206.01	458.25	205.11	114.56	434.4	164.33	370.49	-
Other Current Assets	0	0	-85K	0	-229K	6.91M	14.31M	6M	0
Total Non-Current Assets	2.21M	7.9M	68.83M	120.12M	426.75M	311.78M	292.11M	250.73M	285.71M
Property, Plant & Equipment	1.11M	1.32M	6.61M	19.81M	36.8M	39.2M	32.62M	16.76M	0
Fixed Asset Turnover	9.97x	14.97x	4.14x	2.43x	3.24x	1.94x	2.33x	4.91x	-
Goodwill	0	0	33.64M	58.45M	224.74M	224.74M	224.74M	212.3M	0
Intangible Assets	0	0	21.98M	31.05M	152.15M	32.09M	21.15M	9.56M	0
Long-Term Investments	1.07M	6.55M	2.5M	5.87M	4.37M	6.4M	13.33M	5.62M	0
Other Non-Current Assets	35.84K	36K	3.92M	4.71M	9.81M	9.35M	-20.88M	6.48M	285.71M
Total Assets	12.14M▲ 0%	45.47M▲ 274.4%	93.01M▲ 104.6%	234.83M▲ 152.5%	552.6M▲ 135.3%	450.23M▼ 18.5%	412.71M▼ 8.3%	399.49M▼ 3.2%	405.88M▲ 1.6%
Asset Turnover	0.91x	0.43x	0.29x	0.20x	0.22x	0.17x	0.18x	0.21x	0.24x
Asset Growth %	53.19%	274.43%	104.57%	152.47%	135.32%	-18.53%	-8.33%	-3.2%	1.6%
Total Current Liabilities	1.51M	1.94M	7.78M	15.57M	42.7M	44.58M	42.18M	32.73M	22.98M
Accounts Payable	691K	720K	3.12M	3.67M	14.95M	15.37M	6.94M	3.57M	0
Days Payables Outstanding	58.98	42.27	128.52	64.92	60.4	191.25	26.24	45.63	-
Short-Term Debt	0	0	13K	614K	862K	1.81M	6.29M	10.94M	11.02M
Deferred Revenue (Current)	130K	130K	324K	931K	814K	548K	661K	103K	0
Other Current Liabilities	130K	159K	1.96M	6.34M	21.52M	20.71M	23.21M	5.23M	11.96M
Current Ratio	6.56x	19.37x	3.11x	7.37x	2.95x	3.11x	2.86x	4.54x	5.23x
Quick Ratio	5.34x	17.56x	1.68x	6.62x	2.28x	2.32x	1.83x	3.66x	5.23x
Cash Conversion Cycle	132.49	220.04	401	200.96	125.28	405.62	227.86	365.55	-
Total Non-Current Liabilities	538K	380K	2.21M	14.01M	33.54M	41.46M	32.87M	17.84M	11.02M
Long-Term Debt	0	0	0	655K	6.35M	23.79M	17.56M	5M	0
Capital Lease Obligations	0	0	550K	8.77M	16.76M	15.09M	8.7M	12.72M	0
Deferred Tax Liabilities	0	0	0	0	5.49M	250K	114K	124K	0
Other Non-Current Liabilities	538K	28.9M	0	4.51M	4.94M	2.33M	6.5M	0	11.02M
Total Liabilities	2.05M	2.32M	9.98M	29.58M	76.24M	86.04M	75.05M	50.58M	34M
Total Debt	0	0	1.35M	11.15M	26.88M	43.71M	33.83M	30.17M	11.02M
Net Debt	-6.66M	-30.66M	-5.09M	-79.3M	-42.99M	24.27M	5.93M	-65.21M	11.02M
Debt / Equity	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x	0.03x
Debt / EBITDA	-	-	0.89x	6.42x	-	3.11x	-	19.70x	-
Net Debt / EBITDA	-	-7.66x	-3.33x	-45.68x	-	1.73x	-	-42.57x	-
Interest Coverage	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-12.94x	-9.92x	-4.48x
Total Equity	10.09M▲ 0%	43.15M▲ 327.5%	83.03M▲ 92.4%	205.25M▲ 147.2%	480.75M▲ 134.2%	364.19M▼ 24.2%	337.66M▼ 7.3%	348.91M▲ 3.3%	371.89M▲ 6.6%
Equity Growth %	218.76%	327.55%	92.42%	147.21%	134.23%	-24.25%	-7.28%	3.33%	6.59%
Book Value per Share	0.76	2.65	4.27	7.52	12.49	8.57	7.72	7.57	7.64
Total Shareholders' Equity	10.09M	43.15M	83.03M	205.25M	480.75M	364.19M	337.66M	348.91M	371.89M
Common Stock	14.02K	19K	21K	33K	42K	43K	45K	47K	0
Retained Earnings	-73.96M	-71.03M	-100.05M	-97.39M	-105.02M	-246.91M	-313.34M	-335.1M	-339.7M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.01M	-2.33M	0	0	-282K	-679K	-345K	24K	0
Minority Interest	0	0	0	0	0	0	0	0	0

BLFS Cash Flow Statement

BioLife Solutions, Inc. (BLFS) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	605K	2.35M	1.21M	6.51M	-4.84M	-8.49M	-12.5M	8.43M	20.11M
Operating CF Margin %	5.49%	11.89%	4.43%	13.55%	-4.06%	-11.13%	-16.48%	10.25%	20.91%
Operating CF Growth %	113.98%	288.1%	-48.34%	437.1%	-174.23%	-75.54%	-47.23%	167.46%	138.58%
Net Income	-2.52M	3.27M	-1.66M	2.67M	-7.63M	-139.81M	-66.43M	-20.18M	0
Depreciation & Amortization	338.68K	338K	1.8M	5.07M	12.87M	16.47M	12.29M	5.49M	0
Stock-Based Compensation	1.27M	1.52M	3.04M	5.98M	13.96M	25.33M	31.67M	30.92M	0
Deferred Taxes	1M	672K	-1.54M	-3.3M	-20.13M	-5.24M	-62K	-64K	0
Other Non-Cash Items	203.54K	-127K	4.04M	-2.12M	-1.64M	109.65M	8.56M	-7.96M	20.11M
Working Capital Changes	302.93K	-3.32M	-4.47M	-1.78M	-2.26M	-14.9M	1.47M	227K	0
Change in Receivables	172.33K	-2.02M	-290K	-1.79M	-10.13M	-10.75M	15.35M	-2.9M	0
Change in Inventory	-88.96K	-1.66M	-3.78M	-629K	114K	-6.56M	-8.55M	781K	0
Change in Payables	20.58K	-11K	768K	-171K	2.02M	414K	-8.43M	26K	0
Cash from Investing	-144K	-6.5M	-27.02M	-23.73M	-12.64M	-58.12M	17.84M	58.3M	-71.54M
Capital Expenditures	-143.77K	-500K	-675K	-4.63M	-8.38M	-10.38M	-6.38M	-3.23M	0
CapEx % of Revenue	1.3%	2.53%	2.47%	9.63%	7.04%	13.62%	8.41%	3.92%	-
Acquisitions	0	-6M	-22.19M	-15.94M	1.56M	0	0	60.39M	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-233	-6M	-1.66M	-3.17M	-5.82M	-3.54M	-4.86M	-2.37M	-71.54M
Cash from Financing	4.8M	28.15M	1.6M	102.08M	-2.78M	16.32M	10.59M	-6.78M	-10.92M
Debt Issued (Net)	976K	0	0	984K	-2.89M	17.84M	-498K	-6.61M	0
Equity Issued (Net)	0	1000K	0	1000K	1000K	192K	1000K	202K	0
Dividends Paid	-106.25K	-436K	0	0	0	0	0	0	0
Share Repurchases	0	-4.25M	0	0	0	0	0	0	0
Other Financing	3.93M	12.83M	1.6M	973K	-1.16M	-1.71M	845K	-377K	-10.92M
Net Change in Cash	5.26M▲ 0%	23.99M▲ 356.4%	-24.21M▼ 200.9%	84.01M▲ 447.0%	-20.59M▼ 124.5%	-50.4M▼ 144.8%	15.96M▲ 131.7%	59.95M▲ 275.5%	-62.35M▼ 204.0%
Free Cash Flow	461.23K▲ 0%	1.85M▲ 300.7%	538K▼ 70.9%	1.88M▲ 249.8%	-13.22M▼ 802.5%	-18.87M▼ 42.8%	-18.88M▼ 0.0%	5.2M▲ 127.6%	20.11M▲ 286.5%
FCF Margin %	4.18%	9.36%	1.97%	3.91%	-11.1%	-24.76%	-24.89%	6.33%	20.91%
FCF Growth %	108.26%	300.67%	-70.89%	249.81%	-802.5%	-42.76%	-0.03%	127.56%	286.53%
FCF per Share	0.03	0.11	0.03	0.07	-0.34	-0.44	-0.43	0.11	0.41
FCF Conversion (FCF/Net Income)	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x	-1.66x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

BLFS Key Ratios

BioLife Solutions, Inc. (BLFS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-105.56%	-37.94%	12.27%	-2.63%	1.85%	-2.6%	-33.09%	-18.93%	-5.88%	-3.37%
Return on Invested Capital (ROIC)	-68.4%	-19.72%	34.5%	-1.3%	-2.45%	-9.36%	-1.08%	-4.8%	-1.7%	-2.73%
Gross Margin	58.09%	61.2%	68.51%	67.64%	57.07%	24.21%	61.53%	61.63%	65.25%	64.56%
Net Margin	-83.57%	-22.82%	16.54%	-6.05%	5.55%	-7.48%	-183.38%	-87.57%	-24.54%	-12.61%
Debt / Equity	0.90x	-	-	0.02x	0.05x	0.06x	0.12x	0.10x	0.09x	0.03x
Interest Coverage	-15.24x	-2.32x	732.40x	-156.20x	-185.11x	-72.49x	-8.62x	-12.94x	-9.92x	-4.48x
FCF Conversion	0.63x	-0.24x	0.72x	-0.73x	2.44x	0.54x	0.06x	0.19x	-0.42x	-1.66x
Revenue Growth	27.57%	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	-0.5%	8.44%	16.97%

BLFS SEC Filings & Documents

BioLife Solutions, Inc. (BLFS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 2, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 3, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

BLFS Frequently Asked Questions

BioLife Solutions, Inc. (BLFS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

BioLife Solutions, Inc. (BLFS) reported $96.2M in revenue for fiscal year 2025. This represents a 608% increase from $13.6M in 1995.

BioLife Solutions, Inc. (BLFS) grew revenue by 17.0% over the past year. This is strong growth.

BioLife Solutions, Inc. (BLFS) reported a net loss of $12.1M for fiscal year 2025.

Dividend & Returns

BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.

BioLife Solutions, Inc. (BLFS) generated $12.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More BLFS

BioLife Solutions, Inc. (BLFS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

BioLife Solutions, Inc.(BLFS)Earnings, Financials & Key Ratios

BLFS Key Insights

✓Strengths

✗Weaknesses

BLFS Price & Volume

BLFS Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

BLFS Recent Earnings

BLFS Peer Comparison

Compare BLFS vs Peers

vs BFLY

vs TMO

Compare Top 5

BLFS Income Statement

BLFS Balance Sheet

BLFS Cash Flow Statement

BLFS Key Ratios

BLFS SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

BLFS Frequently Asked Questions

Explore More BLFS

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation